Sanofi ' s GLP-1/Insulin Combo LixiLan Faces 3-Month Delay in US Sanofi ' s GLP-1/Insulin Combo LixiLan Faces 3-Month Delay in US

US approval of the GLP-1 receptor agonist lixisenatide and insulin glargine combination LixiLan is delayed over concerns about the delivery device; a decision is now due by November.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news